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In the present issue of Critical Care, Dr Heininger and 
colleagues present a new study in which they assessed the 
clinical outcomes of nonimmunosuppressed critically ill 
patients with severe sepsis who had reactivation of cyto-
megalovirus (CMV) [1]. Th  ey found that intensive care 
unit (ICU) stay, hospital stay and mechanical ventilation 
were all signiﬁ  cantly prolonged in patients with CMV 
reactivation compared with those without reactivation, 
but the mortality rate was not diﬀ  erent between groups. 
How can this be explained?
CMV serology is positive in over two-thirds of the 
healthy population based on epidemiological studies 
[2-4]. Similar to other herpes viruses, once an individual 
acquires CMV (mostly during infancy) the virus stays in a 
dormant phase for this individual’s entire life. Conditions 
that lower the immune system guard may allow the 
dormant CMV to start replicating and lead to reactivation 
and an infectious state. Examples of these conditions 
include use of immunosuppressive drugs such as chemo-
therapy for cancer or anti-rejection therapy for organ 
transplant recipients.
Patients immunocompetent before ICU admission may 
become immunosuppressed due to severe sepsis [5,6], 
predisposing them to reactivation of viruses such as 
CMV. Th   is hypo  thesis was supported by the results of a 
meta-analysis from our group [7], showing that the rate 
of CMV infec  tion is inﬂ  uenced by the sensitivity of the 
diagnostic method, the type of ICU, disease severity, and 
the timing of CMV screening after ICU admission. We 
found that ICU patients with positive CMV serology at 
admission who stayed more than 5 days in the unit or 
who were admitted with severe sepsis were signiﬁ  cantly 
more prone to have active CMV infection with a 
prevalence up to 36%. In addition, we found that patients 
with active CMV infection had signiﬁ  cantly  higher 
mortality than patients without CMV infection (1.93, 
95% conﬁ  dence interval = 1.29, 2.88; P = 0.001). If such a 
higher mortality could be attributed to CMV or was in 
part secondary to CMV, then the results of severe sepsis 
trials could be substantially con  founded from the very 
beginning [8]. In other words, even a small imbalance in 
CMV reactivation between control and treatment arms 
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Cytomegalovirus (CMV) is a ubiquitous virus present 
in approximately two-thirds of the healthy population. 
This virus rarely causes an active disease in healthy 
individuals, but it is among the most common 
opportunistic infections in immunocompromised 
patients such as solid organ transplant recipients, 
patients receiving chemotherapy for cancer or patients 
with human immunodefi  ciency virus. Critically ill 
patients who are immunocompetent before intensive 
care unit admission may also become more prone to 
develop active CMV infection if they have prolonged 
hospitalizations, high disease severity, and severe 
sepsis. The development of active CMV infection in 
these critically ill patients has been associated with a 
signifi  cantly higher risk of death in several previous 
studies. The present issue of Critical Care brings a 
new study by Heininger and colleagues in which the 
authors found that patients with severe sepsis who 
developed active CMV infection had signifi  cantly 
longer intensive care unit and hospital stays, prolonged 
mechanical ventilation, but no changes in mortality 
compared to patients without CMV infection. We 
discuss the possible reasons for their fi  ndings (for 
example, selection bias and low (20%) statistical power 
to detect mortality endpoints), and also perform an 
update of our previous meta-analysis with the addition 
of Heininger and colleagues’ study to verify whether 
the higher mortality rate with CMV holds. Our updated 
meta-analysis with approximately 1,000 patients shows 
that active CMV infection continues to be associated 
with a signifi  cant 81% higher mortality rate than that in 
critically ill patients without active CMV infection.
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© 2011 BioMed Central Ltdcould lead to signiﬁ  cant false-positive results due to more 
active CMV infection and higher mortality in the control 
arm; or to false-negative results due to more active CMV 
infection and higher mortality in the treatment arm.
Th   is new study by Heininger and colleagues showed a 
signiﬁ  cant association between active CMV infection and 
major morbidity ﬁ  ndings such as prolonged ICU/hospital 
stay and mechanical ventilation, but no increased mor-
tality [1]. Even though this was a well-performed obser-
va  tional study, however, the lack of randomization 
probably led to selection bias; for example, patients 
without active CMV infection compared with patients 
with active CMV infection had more septic shock and 
peritonitis, less urinary tract infections, and higher 
Simpliﬁ  ed Acute Physiology Score II/Sequential Organ 
Failure Assessment scores – all of which are known to be 
associated with higher mortality. Hence, this small 
nonrandomized study could easily have been confounded 
by these important baseline imbalances, which could be 
the reason for false-negative results; that is, the more 
severely ill patients (due to baseline imbalances) without 
active CMV infection did not allow the study to detect 
the expected higher mortality in patients with active 
CMV infection.
Also, based on Heininger and colleagues’ small sample 
size, the statistical power to detect diﬀ  erences in mor-
tality between groups was extremely low (20%), which 
could have further increased the probability of false-
negative results. If we assume that this high likelihood of 
false-negative results is true, then the addition of this 
new study to our previous meta-analysis should not 
change our previous results of higher mortality with 
active CMV infection. If we assume that their results are 
not false-negative, then the addition of this negative 
study should change the results of our meta-analysis. In 
order to clarify this assumption, we performed an update 
of the mortality analysis from our previous study. To be 
com  plete, we also added the study by Chiche and 
colleagues that was published after our meta-analysis [9]. 
Two more studies were thus added to our initial meta-
analysis and the results are shown in Figure 1. Our 
updated results consistently show that active CMV 
infection continues to be associated with a signiﬁ  cant 
81% higher mortality rate than that in patients without 
active CMV infection. Th  is  ﬁ  nding strongly suggests the 
results from Heininger and colleagues were false-negative 
with respect to mortality outcomes. In fact, their worse 
morbidity outcomes in patients with active CMV 
infection ﬁ  t perfectly with both previous studies and our 
recent meta-analysis, as well as with the higher mortality 
seen in patients with active CMV infection.
Based on all current evidence, it is unquestionable that 
active CMV infection is associated with higher morbidity 
and higher mortality in critically ill patients who were 
not previously immunosuppressed. Nonetheless, the 
million-dollar question still remains to be answered: is 
CMV causing mortality or is CMV accompanying 
mortality (that is, reﬂ  ecting higher severity of illness)? 
Only a large prospective, randomized, non-interventional 
cohort study with adequate statistical power and compre-
hensive study design as previously recommended [8], can 
bring light to resolve such an important issue for our 
critically ill patients.
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Figure 1. Active cytomegalovirus infection: all-cause mortality. Z = 3.62; P = 0.0003; Q = 10.01; I2 = 10.9%. CI, confi  dence interval; CMV, 
cytomegalovirus; MH, Mantel–Haenszel.
Study name Statistics for each study Deaths  / Total MH odds ratio and 95% CI
MH odds Lower Upper Active CMV No active MH odds  Lower  Upper  Active CMV  No active 
ratio limit limit P value infection CMV infection
Domart Y 1990 2.18 0.93 5.13 0.0731 16 / 29 31 / 86
Kutza A 1998 0.62 0.13 2.88 0.5400 7 / 11 17 / 23
Heininger A 2001 2.16 0.71 6.58 0.1744 11 / 20 13 / 36
Cook C 2003 2.76 0.74 10.35 0.1321 5 / 10 25 / 94
J b S 2005 26 4 10 4 66 9 0 0412 20 / 40 11 / 40 Jaber S 2005 2.64 1.04 6.69 0.0412 20 / 40 11 / 40
von Mueller L 2006 3.06 0.53 17.46 0.2091 5 / 8 6 / 17
Limaye A 2008 0.21 0.03 1.72 0.1465 1 / 39 9 / 81
Ziemann M 2008 3.26 1.11 9.54 0.0312 10 / 35 7 / 64
Chiche L 2009 2.08 1.04 4.17 0.0396 23 / 39 83 / 203
Heininger A 2011 1.08 0.44 2.65 0.8608 13 / 35 18 / 51
1.81 1.31 2.50 0.0003 111 / 266 220 / 695
0.1 0.2 0.5 1 2 5 10
No active CMV infection Active CMV  infection
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